Does the media favor ALNY or MDGL?

In the previous week, Alnylam Pharmaceuticals had 5 more articles in the media than Madrigal Pharmaceuticals. MarketBeat recorded 16 mentions for Alnylam Pharmaceuticals and 11 mentions for Madrigal Pharmaceuticals. Alnylam Pharmaceuticals' average media sentiment score of 1.61 beat Madrigal Pharmaceuticals' score of 0.68 indicating that Alnylam Pharmaceuticals is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Alnylam Pharmaceuticals 11 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive Madrigal Pharmaceuticals 3 Very Positive mention(s) 3 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media refer more to MDGL or BIIB?

In the previous week, Biogen had 6 more articles in the media than Madrigal Pharmaceuticals. MarketBeat recorded 17 mentions for Biogen and 11 mentions for Madrigal Pharmaceuticals. Madrigal Pharmaceuticals' average media sentiment score of 0.68 beat Biogen's score of 0.25 indicating that Madrigal Pharmaceuticals is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Madrigal Pharmaceuticals 3 Very Positive mention(s) 3 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Biogen 2 Very Positive mention(s) 2 Positive mention(s) 11 Neutral mention(s) 0 Negative mention(s) 1 Very Negative mention(s) Neutral

Does the media favor MDGL or UTHR?

In the previous week, United Therapeutics had 9 more articles in the media than Madrigal Pharmaceuticals. MarketBeat recorded 20 mentions for United Therapeutics and 11 mentions for Madrigal Pharmaceuticals. Madrigal Pharmaceuticals' average media sentiment score of 0.68 beat United Therapeutics' score of 0.48 indicating that Madrigal Pharmaceuticals is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Madrigal Pharmaceuticals 3 Very Positive mention(s) 3 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive United Therapeutics 10 Very Positive mention(s) 2 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Does the media prefer INCY or MDGL?

In the previous week, Incyte had 1 more articles in the media than Madrigal Pharmaceuticals. MarketBeat recorded 12 mentions for Incyte and 11 mentions for Madrigal Pharmaceuticals. Madrigal Pharmaceuticals' average media sentiment score of 0.68 beat Incyte's score of 0.44 indicating that Madrigal Pharmaceuticals is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Incyte 5 Very Positive mention(s) 2 Positive mention(s) 1 Neutral mention(s) 2 Negative mention(s) 1 Very Negative mention(s) Neutral Madrigal Pharmaceuticals 3 Very Positive mention(s) 3 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Madrigal Pharmaceuticals (MDGL) Competitors

$488.15 +35.29 (+7.79%)

Closing price 04:00 PM Eastern

Extended Trading

$484.74 -3.41 (-0.70%)

As of 05:10 PM Eastern

Compare

MDGL vs. ALNY, BIIB, UTHR, INCY, and NBIX

Should you buy Madrigal Pharmaceuticals stock or one of its competitors? MarketBeat compares Madrigal Pharmaceuticals with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Madrigal Pharmaceuticals include Alnylam Pharmaceuticals (ALNY), Biogen (BIIB), United Therapeutics (UTHR), Incyte (INCY), and Neurocrine Biosciences (NBIX). These companies are all part of the "biotechnology" industry.

How does Madrigal Pharmaceuticals compare to Alnylam Pharmaceuticals?

Alnylam Pharmaceuticals (NASDAQ:ALNY) and Madrigal Pharmaceuticals (NASDAQ:MDGL) are both large-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their risk, valuation, profitability, earnings, analyst recommendations, media sentiment, institutional ownership and dividends.

In the previous week, Alnylam Pharmaceuticals had 5 more articles in the media than Madrigal Pharmaceuticals. MarketBeat recorded 16 mentions for Alnylam Pharmaceuticals and 11 mentions for Madrigal Pharmaceuticals. Alnylam Pharmaceuticals' average media sentiment score of 1.61 beat Madrigal Pharmaceuticals' score of 0.68 indicating that Alnylam Pharmaceuticals is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Alnylam Pharmaceuticals	11 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive
Madrigal Pharmaceuticals	3 Very Positive mention(s)	3 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Alnylam Pharmaceuticals presently has a consensus price target of $463.13, suggesting a potential upside of 58.29%. Madrigal Pharmaceuticals has a consensus price target of $687.00, suggesting a potential upside of 40.74%. Given Alnylam Pharmaceuticals' stronger consensus rating and higher probable upside, equities research analysts plainly believe Alnylam Pharmaceuticals is more favorable than Madrigal Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Alnylam Pharmaceuticals	0 Sell rating(s)	6 Hold rating(s)	18 Buy rating(s)	2 Strong Buy rating(s)	2.85
Madrigal Pharmaceuticals	1 Sell rating(s)	3 Hold rating(s)	13 Buy rating(s)	1 Strong Buy rating(s)	2.78

Alnylam Pharmaceuticals has higher revenue and earnings than Madrigal Pharmaceuticals. Madrigal Pharmaceuticals is trading at a lower price-to-earnings ratio than Alnylam Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Alnylam Pharmaceuticals	$3.71B	10.52	$313.75M	$3.66	79.94
Madrigal Pharmaceuticals	$958.40M	11.75	-$288.28M	-$12.80	N/A

93.0% of Alnylam Pharmaceuticals shares are owned by institutional investors. Comparatively, 98.5% of Madrigal Pharmaceuticals shares are owned by institutional investors. 0.9% of Alnylam Pharmaceuticals shares are owned by company insiders. Comparatively, 17.6% of Madrigal Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Alnylam Pharmaceuticals has a net margin of 11.72% compared to Madrigal Pharmaceuticals' net margin of -27.32%. Alnylam Pharmaceuticals' return on equity of 85.76% beat Madrigal Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Alnylam Pharmaceuticals	11.72%	85.76%	10.32%
Madrigal Pharmaceuticals	-27.32%	-50.15%	-25.44%

Alnylam Pharmaceuticals has a beta of 0.29, meaning that its stock price is 71% less volatile than the broader market. Comparatively, Madrigal Pharmaceuticals has a beta of -1.07, meaning that its stock price is 207% less volatile than the broader market.

Summary

Alnylam Pharmaceuticals beats Madrigal Pharmaceuticals on 14 of the 17 factors compared between the two stocks.

How does Madrigal Pharmaceuticals compare to Biogen?

Madrigal Pharmaceuticals (NASDAQ:MDGL) and Biogen (NASDAQ:BIIB) are both large-cap medical companies, but which is the better stock? We will contrast the two companies based on the strength of their media sentiment, profitability, institutional ownership, valuation, earnings, dividends, analyst recommendations and risk.

Biogen has higher revenue and earnings than Madrigal Pharmaceuticals. Madrigal Pharmaceuticals is trading at a lower price-to-earnings ratio than Biogen, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Madrigal Pharmaceuticals	$958.40M	11.75	-$288.28M	-$12.80	N/A
Biogen	$9.89B	2.93	$1.29B	$9.32	21.03

Biogen has a net margin of 13.81% compared to Madrigal Pharmaceuticals' net margin of -27.32%. Biogen's return on equity of 12.83% beat Madrigal Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Madrigal Pharmaceuticals	-27.32%	-50.15%	-25.44%
Biogen	13.81%	12.83%	8.01%

98.5% of Madrigal Pharmaceuticals shares are held by institutional investors. Comparatively, 87.9% of Biogen shares are held by institutional investors. 17.6% of Madrigal Pharmaceuticals shares are held by company insiders. Comparatively, 0.3% of Biogen shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Madrigal Pharmaceuticals has a beta of -1.07, meaning that its stock price is 207% less volatile than the broader market. Comparatively, Biogen has a beta of 0.2, meaning that its stock price is 80% less volatile than the broader market.

In the previous week, Biogen had 6 more articles in the media than Madrigal Pharmaceuticals. MarketBeat recorded 17 mentions for Biogen and 11 mentions for Madrigal Pharmaceuticals. Madrigal Pharmaceuticals' average media sentiment score of 0.68 beat Biogen's score of 0.25 indicating that Madrigal Pharmaceuticals is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Madrigal Pharmaceuticals	3 Very Positive mention(s)	3 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Biogen	2 Very Positive mention(s)	2 Positive mention(s)	11 Neutral mention(s)	0 Negative mention(s)	1 Very Negative mention(s)	Neutral

Madrigal Pharmaceuticals currently has a consensus price target of $687.00, indicating a potential upside of 40.74%. Biogen has a consensus price target of $215.81, indicating a potential upside of 10.13%. Given Madrigal Pharmaceuticals' stronger consensus rating and higher possible upside, analysts clearly believe Madrigal Pharmaceuticals is more favorable than Biogen.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Madrigal Pharmaceuticals	1 Sell rating(s)	3 Hold rating(s)	13 Buy rating(s)	1 Strong Buy rating(s)	2.78
Biogen	1 Sell rating(s)	13 Hold rating(s)	14 Buy rating(s)	1 Strong Buy rating(s)	2.52

Summary

Biogen beats Madrigal Pharmaceuticals on 10 of the 16 factors compared between the two stocks.

How does Madrigal Pharmaceuticals compare to United Therapeutics?

Madrigal Pharmaceuticals (NASDAQ:MDGL) and United Therapeutics (NASDAQ:UTHR) are both large-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their media sentiment, profitability, valuation, dividends, earnings, analyst recommendations, institutional ownership and risk.

Madrigal Pharmaceuticals has a beta of -1.07, indicating that its stock price is 207% less volatile than the broader market. Comparatively, United Therapeutics has a beta of 0.57, indicating that its stock price is 43% less volatile than the broader market.

In the previous week, United Therapeutics had 9 more articles in the media than Madrigal Pharmaceuticals. MarketBeat recorded 20 mentions for United Therapeutics and 11 mentions for Madrigal Pharmaceuticals. Madrigal Pharmaceuticals' average media sentiment score of 0.68 beat United Therapeutics' score of 0.48 indicating that Madrigal Pharmaceuticals is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Madrigal Pharmaceuticals	3 Very Positive mention(s)	3 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
United Therapeutics	10 Very Positive mention(s)	2 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

98.5% of Madrigal Pharmaceuticals shares are owned by institutional investors. Comparatively, 94.1% of United Therapeutics shares are owned by institutional investors. 17.6% of Madrigal Pharmaceuticals shares are owned by insiders. Comparatively, 8.6% of United Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

United Therapeutics has higher revenue and earnings than Madrigal Pharmaceuticals. Madrigal Pharmaceuticals is trading at a lower price-to-earnings ratio than United Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Madrigal Pharmaceuticals	$958.40M	11.75	-$288.28M	-$12.80	N/A
United Therapeutics	$3.18B	7.33	$1.33B	$27.09	20.28

United Therapeutics has a net margin of 40.62% compared to Madrigal Pharmaceuticals' net margin of -27.32%. United Therapeutics' return on equity of 19.24% beat Madrigal Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Madrigal Pharmaceuticals	-27.32%	-50.15%	-25.44%
United Therapeutics	40.62%	19.24%	17.25%

Madrigal Pharmaceuticals currently has a consensus target price of $687.00, suggesting a potential upside of 40.74%. United Therapeutics has a consensus target price of $619.42, suggesting a potential upside of 12.73%. Given Madrigal Pharmaceuticals' higher possible upside, analysts clearly believe Madrigal Pharmaceuticals is more favorable than United Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Madrigal Pharmaceuticals	1 Sell rating(s)	3 Hold rating(s)	13 Buy rating(s)	1 Strong Buy rating(s)	2.78
United Therapeutics	0 Sell rating(s)	2 Hold rating(s)	11 Buy rating(s)	0 Strong Buy rating(s)	2.85

Summary

United Therapeutics beats Madrigal Pharmaceuticals on 10 of the 17 factors compared between the two stocks.

How does Madrigal Pharmaceuticals compare to Incyte?

Incyte (NASDAQ:INCY) and Madrigal Pharmaceuticals (NASDAQ:MDGL) are both large-cap medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their institutional ownership, earnings, risk, profitability, valuation, analyst recommendations, media sentiment and dividends.

Incyte has a beta of 0.79, suggesting that its stock price is 21% less volatile than the broader market. Comparatively, Madrigal Pharmaceuticals has a beta of -1.07, suggesting that its stock price is 207% less volatile than the broader market.

In the previous week, Incyte had 1 more articles in the media than Madrigal Pharmaceuticals. MarketBeat recorded 12 mentions for Incyte and 11 mentions for Madrigal Pharmaceuticals. Madrigal Pharmaceuticals' average media sentiment score of 0.68 beat Incyte's score of 0.44 indicating that Madrigal Pharmaceuticals is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Incyte	5 Very Positive mention(s)	2 Positive mention(s)	1 Neutral mention(s)	2 Negative mention(s)	1 Very Negative mention(s)	Neutral
Madrigal Pharmaceuticals	3 Very Positive mention(s)	3 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

97.0% of Incyte shares are owned by institutional investors. Comparatively, 98.5% of Madrigal Pharmaceuticals shares are owned by institutional investors. 16.2% of Incyte shares are owned by insiders. Comparatively, 17.6% of Madrigal Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Incyte currently has a consensus price target of $104.00, indicating a potential upside of 6.14%. Madrigal Pharmaceuticals has a consensus price target of $687.00, indicating a potential upside of 40.74%. Given Madrigal Pharmaceuticals' stronger consensus rating and higher probable upside, analysts plainly believe Madrigal Pharmaceuticals is more favorable than Incyte.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Incyte	1 Sell rating(s)	12 Hold rating(s)	9 Buy rating(s)	0 Strong Buy rating(s)	2.36
Madrigal Pharmaceuticals	1 Sell rating(s)	3 Hold rating(s)	13 Buy rating(s)	1 Strong Buy rating(s)	2.78

Incyte has higher revenue and earnings than Madrigal Pharmaceuticals. Madrigal Pharmaceuticals is trading at a lower price-to-earnings ratio than Incyte, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Incyte	$5.14B	3.81	$1.29B	$7.08	13.84
Madrigal Pharmaceuticals	$958.40M	11.75	-$288.28M	-$12.80	N/A

Incyte has a net margin of 26.71% compared to Madrigal Pharmaceuticals' net margin of -27.32%. Incyte's return on equity of 26.66% beat Madrigal Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Incyte	26.71%	26.66%	19.77%
Madrigal Pharmaceuticals	-27.32%	-50.15%	-25.44%

Summary

Incyte beats Madrigal Pharmaceuticals on 9 of the 17 factors compared between the two stocks.

How does Madrigal Pharmaceuticals compare to Neurocrine Biosciences?

Neurocrine Biosciences (NASDAQ:NBIX) and Madrigal Pharmaceuticals (NASDAQ:MDGL) are both large-cap medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their dividends, earnings, profitability, institutional ownership, media sentiment, analyst recommendations, valuation and risk.

Neurocrine Biosciences has a beta of 0.4, indicating that its stock price is 60% less volatile than the broader market. Comparatively, Madrigal Pharmaceuticals has a beta of -1.07, indicating that its stock price is 207% less volatile than the broader market.

Neurocrine Biosciences has higher revenue and earnings than Madrigal Pharmaceuticals. Madrigal Pharmaceuticals is trading at a lower price-to-earnings ratio than Neurocrine Biosciences, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Neurocrine Biosciences	$2.86B	5.80	$478.60M	$6.49	25.44
Madrigal Pharmaceuticals	$958.40M	11.75	-$288.28M	-$12.80	N/A

Neurocrine Biosciences presently has a consensus price target of $187.52, indicating a potential upside of 13.58%. Madrigal Pharmaceuticals has a consensus price target of $687.00, indicating a potential upside of 40.74%. Given Madrigal Pharmaceuticals' higher possible upside, analysts plainly believe Madrigal Pharmaceuticals is more favorable than Neurocrine Biosciences.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Neurocrine Biosciences	0 Sell rating(s)	5 Hold rating(s)	17 Buy rating(s)	1 Strong Buy rating(s)	2.83
Madrigal Pharmaceuticals	1 Sell rating(s)	3 Hold rating(s)	13 Buy rating(s)	1 Strong Buy rating(s)	2.78

92.6% of Neurocrine Biosciences shares are held by institutional investors. Comparatively, 98.5% of Madrigal Pharmaceuticals shares are held by institutional investors. 4.6% of Neurocrine Biosciences shares are held by company insiders. Comparatively, 17.6% of Madrigal Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

Neurocrine Biosciences has a net margin of 21.55% compared to Madrigal Pharmaceuticals' net margin of -27.32%. Neurocrine Biosciences' return on equity of 19.79% beat Madrigal Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Neurocrine Biosciences	21.55%	19.79%	13.82%
Madrigal Pharmaceuticals	-27.32%	-50.15%	-25.44%

In the previous week, Neurocrine Biosciences had 6 more articles in the media than Madrigal Pharmaceuticals. MarketBeat recorded 17 mentions for Neurocrine Biosciences and 11 mentions for Madrigal Pharmaceuticals. Madrigal Pharmaceuticals' average media sentiment score of 0.68 beat Neurocrine Biosciences' score of 0.29 indicating that Madrigal Pharmaceuticals is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Neurocrine Biosciences	6 Very Positive mention(s)	1 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Madrigal Pharmaceuticals	3 Very Positive mention(s)	3 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

Neurocrine Biosciences beats Madrigal Pharmaceuticals on 11 of the 16 factors compared between the two stocks.

Get Madrigal Pharmaceuticals News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding MDGL and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

MDGL vs. The Competition

Export

Metric	Madrigal Pharmaceuticals	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$10.44B	$2.93B	$6.47B	$12.54B
Dividend Yield	N/A	1.68%	2.69%	5.22%
P/E Ratio	-38.14	17.69	22.39	24.18
Price / Sales	11.75	302.27	520.79	112.26
Price / Cash	N/A	55.72	41.34	57.13
Price / Book	18.39	3.85	9.84	6.72
Net Income	-$288.28M	$75.85M	$3.57B	$337.19M
7 Day Performance	-7.49%	-1.67%	-1.16%	0.48%
1 Month Performance	-4.98%	22.18%	3.85%	5.07%
1 Year Performance	71.64%	21.83%	27.40%	34.25%

Madrigal Pharmaceuticals Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
MDGL Madrigal Pharmaceuticals	2.79 of 5 stars	$488.15 +7.8%	$687.00 +40.7%	+66.1%	$10.44B	$958.40M	N/A	90	News Coverage Analyst Forecast Insider Trade
ALNY Alnylam Pharmaceuticals	4.4161 of 5 stars	$295.63 -2.1%	$463.13 +56.7%	-6.5%	$40.32B	$3.71B	80.77	2,770	Positive News Insider Trade
BIIB Biogen	3.0384 of 5 stars	$192.23 -1.9%	$215.81 +12.3%	+44.0%	$28.94B	$9.89B	20.63	7,500
UTHR United Therapeutics	4.1953 of 5 stars	$544.62 -2.2%	$619.42 +13.7%	+65.9%	$23.64B	$3.17B	20.10	1,400	Insider Trade
INCY Incyte	4.2099 of 5 stars	$95.59 -1.2%	$104.00 +8.8%	+41.2%	$19.33B	$5.14B	13.50	2,844	Analyst Forecast

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:MDGL) was last updated on 6/3/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Madrigal Pharmaceuticals (MDGL) Competitors

MDGL vs. ALNY, BIIB, UTHR, INCY, and NBIX

How does Madrigal Pharmaceuticals compare to Alnylam Pharmaceuticals?

Summary

How does Madrigal Pharmaceuticals compare to Biogen?

Summary

How does Madrigal Pharmaceuticals compare to United Therapeutics?

Summary

How does Madrigal Pharmaceuticals compare to Incyte?

Summary

How does Madrigal Pharmaceuticals compare to Neurocrine Biosciences?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

MDGL vs. The Competition

Madrigal Pharmaceuticals Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Madrigal Pharmaceuticals (MDGL) Competitors

MDGL vs. ALNY, BIIB, UTHR, INCY, and NBIX

How does Madrigal Pharmaceuticals compare to Alnylam Pharmaceuticals?

Does the media favor ALNY or MDGL?

Do analysts rate ALNY or MDGL?

Which has better earnings and valuation, ALNY or MDGL?

Do institutionals & insiders hold more shares of ALNY or MDGL?

Is ALNY or MDGL more profitable?

Which has more risk and volatility, ALNY or MDGL?

Summary

How does Madrigal Pharmaceuticals compare to Biogen?

Which has higher earnings and valuation, MDGL or BIIB?

Is MDGL or BIIB more profitable?

Do institutionals & insiders believe in MDGL or BIIB?

Which has more risk & volatility, MDGL or BIIB?

Does the media refer more to MDGL or BIIB?

Do analysts prefer MDGL or BIIB?

Summary

How does Madrigal Pharmaceuticals compare to United Therapeutics?

Which has more volatility and risk, MDGL or UTHR?

Does the media favor MDGL or UTHR?

Do institutionals & insiders have more ownership in MDGL or UTHR?

Which has preferable earnings and valuation, MDGL or UTHR?

Is MDGL or UTHR more profitable?

Do analysts prefer MDGL or UTHR?

Summary

How does Madrigal Pharmaceuticals compare to Incyte?

Which has more risk & volatility, INCY or MDGL?

Does the media prefer INCY or MDGL?

Do insiders and institutionals have more ownership in INCY or MDGL?

Do analysts recommend INCY or MDGL?

Which has better earnings and valuation, INCY or MDGL?

Is INCY or MDGL more profitable?

Summary

How does Madrigal Pharmaceuticals compare to Neurocrine Biosciences?

Which has more volatility and risk, NBIX or MDGL?

Which has better earnings & valuation, NBIX or MDGL?

Do analysts prefer NBIX or MDGL?

Do insiders and institutionals believe in NBIX or MDGL?

Is NBIX or MDGL more profitable?

Does the media refer more to NBIX or MDGL?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

MDGL vs. The Competition

Madrigal Pharmaceuticals Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools